Background and Purpose-Because of a shortage of stroke specialists, many outlying or "spoke" hospitals initiate intravenous (IV) thrombolysis using telemedicine or telephone consultation before transferring patients to a regional stroke center (RSC) hub. We analyzed complications and outcomes of patients treated with IV tissue plasminogen activator (tPA) using the "drip and ship" approach compared to those treated directly at the RSC. Methods-A retrospective review of our Get With the Guidelines Stroke (GWTG-Stroke) database from 01/2003 to 03/2008 identified 296 patients who received IV tPA within 3 hours of symptom onset without catheter-based reperfusion. GWTG-Stroke definitions for symptomatic intracranial (sICH), systemic hemorrhage, discharge functional status, and destination were applied. Follow-up modified Rankin Score was recorded when available. Results-Of 296 patients, 181 (61.1%) had tPA infusion started at an outside spoke hospital (OSH) and 115 (38.9%) at the RSC hub. OSH patients were younger with fewer severe strokes than RSC patients. Patients treated based on telestroke were more frequently octogenarians than patients treated based on a telephone consult. Mortality, sICH, and functional outcomes were not different between OSH versus RSC and telephone versus telestroke patients. Among survivors, mean length of stay was shorter for OSH patients but discharge status was similar and 75% of patients walked independently at discharge. Conclusions-Outcomes in OSH "drip and ship" patients treated in a hub-and-spoke network were comparable to those treated directly at an RSC. These data suggest that "drip and ship" is a safe and effective method to shorten time to treatment with IV tPA. (Stroke. 2010;41:e18-e24.)
I
ntravenous tissue plasminogen activator (IV tPA) is FDA approved for acute ischemic stroke (AIS) within the first 3 hours of symptom onset. 1 Previous studies have shown that IV tPA is underused and that only 3% to 4% of AIS patients receive thrombolytic treatment. 2 A majority of acute stroke patients present to hospitals that lack 24/7 availability of a stroke specialist, 3, 4 are managed by generalists, 5 and many do not receive tPA at the presenting facility. 6, 7 If practitioners opt for transfer to a regional stroke center (RSC) for initiation of tPA, delays may preclude delivery of tPA.
Hub-and-spoke networks have been developed to allow IV tPA to be initiated at an outlying spoke hospital (OSH) under the supervision of a vascular neurologist at the designated RSC hub who provides assistance in the diagnosis and management of AIS via telephone 8 or telemedicine-enabled ("telestroke") 9 consultation before transfer. This practice has been referred to as "drip and ship." 10 The evidence supporting telemedicine for acute stroke care within a hub and spoke network has recently been reviewed and guideline recommendations published. 11, 12 Limited data exist comparing the safety and feasibility of patients treated by "drip and ship" 13 versus patients who arrive directly at the RSC for tPA, or the methods of consultation.
Methods

Patient Selection
All AIS patients at our RSC are prospectively identified and entered in our Get With the Guidelines-Stroke (GWTG-Stroke) quality improvement database during their admission. 14 Because deidentified data are collected for quality improvement purposes, only data available in the medical record is abstracted and our institutional review board has waived the need for informed consent and approved the analysis of our GWTG-Stroke database. We identified all patients admitted to our RSC hospital from 01/03 to 03/08 who received IV tPA at our hospital or at an OSH under our direct supervision before transfer, and without subsequent catheter-based reperfusion therapy.
Telestroke System
Twelve of the 33 referring OSHs in this report had an established telemedicine connection with our hospital during the study period; the remainder used telephone. All consultations are captured in our online acute stroke log. Our telemedicine program uses full motion, interactive videoconferencing with teleradiology, training and education, system maintenance, and case feedback, and has been previously described. 9, 15 Hospitals requesting acute stroke consultation from our RSC hub by telephone receive the same instructions regarding eligibility as hospitals that use telemedicine (see Table 1 for inclusion and exclusion criteria of tPA use in our hospital). The instructions to OSHs include post-tPA care management advice. After all intravenous tPA administration using telephone or telemedicine consult, the treating physicians at our RSC hub reviews with the emergency physician at the OSH the importance of post tPA care, and basic immediate recommendations such as blood pressure parameters, and avoidance of invasive procedures, and antiplatelet and anticoagulant use. Clinical informed consent for tPA was obtained in all cases.
Outcomes Assessment
Post-tPA symptomatic intracranial hemorrhages (sICH) were classified according to the European Cooperative Acute Stroke Study (ECASS) 16 and GWTG-Stroke criteria (clinical worsening within 36 hours of tPA attributable to hemorrhage) by our institutional acute stroke quality taskforce. When available, follow-up modified Rankin Scores (mRS) were abstracted. mRS were extracted from patient records by a trained physician abstractor. 17 No patients were contacted for the purpose of this study, but the social security death index was searched. Death between discharge and 3 months was assigned to the 3-month time point, between 3 to 6 months to the 6-month time point, and between 6 to 12 months to the 12-month time point. • Acute ischemic stroke symptoms with onset or last known well, clearly defined, less than 3 hours before t-PA will be given Contraindications include any of the following
• SBP greater than 185 or DBP greater than 110 mm Hg (see BP Management) (despite medical intervention to lower it)
• Seizure at onset (if residual deficits are attributable to the postictal state rather than to ischemia. If rapid diagnosis of vascular occlusion can be made, treatment may be given).
• Recent surgery/trauma (less than 15 days)
• Recent intracranial or spinal surgery, head trauma, or stroke (less than 3 months)
• History of intracranial hemorrhage or brain aneurysm or vascular malformation or brain tumor (may consider iv tPA in patients with CNS lesions that have a very low likelihood of bleeding such as small unruptured aneurysms or benign tumors with low vascularity)
• Active internal bleeding (less than 22 days)
• (including arterial puncture at a non-compressible site)
• Platelets less than 100 000, PTT greater than 40 sec after heparin use, or PT greater than 15 or INR greater than 1.7, or known bleeding diathesis (see protocol for starting tPA while awaiting results of PT/PTT)
• Suspicion of subarachnoid hemorrhage (by imaging or clinical presentation)
• CT findings (ICH, SAH, or major acute infarct signs) (eg, hypodensity greater than 1/3 cerebral hemisphere)
Warnings (conditions that may increase the risk of unfavorable outcomes but are not necessarily a contraindication to treatment)
• Stroke severity -too severe (eg, NIHSS greater than 22) (At MGH, we typically do not exclude patients based on an increased NIHSS alone).
• Glucose less than 50 or greater than 400 mg/dl (if residual deficits are due to the altered metabolic state rather than to ischemia. If rapid diagnosis of vascular occlusion can be made, treatment may be given)
• Left heart thrombus documented
• Increased risk of bleeding due to any of the following:
⅜ Acute pericarditis
⅜ Subacute bacterial endocarditis (SBE)
⅜ Hemostatic defects including those secondary to severe hepatic or renal disease
⅜ Pregnancy
⅜ Diabetic hemorrhagic retinopathy, or other hemorrhagic ophthalmic conditions ⅜ Septic thrombophlebitis or occluded AV cannula at seriously infected site ⅜ Patients currently receiving oral anticoagulants, e.g., Warfarin sodium (and INR greater than 1.7)
⅜ Advanced age
• Rapid improvement
• Stroke severity too mild (e.g. anticipate ability to discharge to home)
• Life expectancy less than 1 year or severe co-morbid illness or CMO on admission Adapted from http://www2.massgeneral.org/stopstroke/protocolThromIV.aspx.
Statistical Analysis
Univariate analyses of baseline patient characteristics and discharge outcomes were performed in STATA 9.2 (STATA, Inc) using 2 test, Wilcoxon rank sum test, Fisher exact test, as appropriate. Because follow-up mRS scores were abstracted from the medical record, they were available at either 3, 6, or 12 months after discharge. A nonparametric rank test was used to compare the follow-up mRS levels between RSC patients and OSH patients; and within OSH patients, between the telestroke and telephone consultation methods. This test stratified subjects according to their length of follow-up. We implemented the test using a Cox proportional hazard model, with mRS at follow-up as the "event time," with no censoring, and with follow-up time as the strata. We performed the analysis both with and without patients who died in hospital during their index stroke admission. Multivariable logistic regression was used to correct for imbalances between the groups. Baseline variables significant to PϽ0.1 in univariate analysis (age) or previously shown to strongly influence outcome (onset to TPA time and National Institutes of Health Stroke Scale [NIHSS]) were entered in the model. Because of the variability in follow-up time to mRS, we stratified the rank test by follow-up time (0, 3, 6, or 12 months), but assumed a common effect for hospital, or method, across the strata. For subjects without any follow-up, we fixed their follow-up time to be zero and used their mRS at discharge. Subjects who died in-hospital were assigned a mRS of 6 and follow-up time of 0.
Results
Among 2526 AIS patients admitted from January 2003 to March 2008 to our RSC hub, there were 353 (14.0%) AIS patients who received IV tPA treatment within 3 hours of symptom onset at either an OSH or our RSC hub. Among these patients, 296 (83.9%) received IV tPA without any additional catheter-based reperfusion therapy and were selected for analysis. Forty-one patients received tPA under telephone/telemedicine supervision but were not transferred to our RSC hub. Those patients were not included in our study. Overall, patients were 47.6% male, 94.6% white, and ranged in age from 20 to 102 years (mean 72.3Ϯ13.9), with 35.5% of the patients Ն80 years of age ( Baseline patient demographics, treatment complications, and discharge outcomes were compared between patients who started tPA at OSH versus RSC (Table 2 ). OSH patients were younger (71.5ϩ14.7 versus 73.6ϩ12.4, Pϭ0.05) and less likely to have NIHSS Ͼ20 (11.6% versus 22.6%, Pϭ0.01). There were no significant baseline differences in gender, race, vascular risk factors, baseline ambulatory status, initial mean NIHSS, and onset to tPA time. In unadjusted analyses, there were no differences in treatment complications and discharge outcomes. In OSH versus RSC patients, the rates of sICH (3.87% versus 5.22%, Pϭ0.58), serious systemic hemorrhage (0.55% versus 2.61%, Pϭ0.14), and in-hospital mortality (14.92% versus17.39%, Pϭ0.57) were not different but mean hospital length of stay was shorter (5.91Ϯ3.7 versus 7.63Ϯ6.5, PϽ0.001). Among survivors, ambulatory status at discharge, and discharge disposition did not differ between groups.
Follow-up mRS scores were available in 237/296 (80.1%) patients. These scores were obtained once for each patient, and were acquired at different time points of either discharge (59 patients-19.8%, including all in-hospital deaths), 3 months (116 patients-39.2%), 6 months (101 to 34.2%), or 12 months (20 to 6.8%), in a similar distribution between the OSH versus RSC hub patients. Lack of follow-up mRS was more common in OSH than RSC patients (32.1% versus 15%, Pϭ0.004). RSC patients without follow-up had similar age, prestroke ambulation status, presenting NIHSS, use of telestroke, tPA complications, length of stay, in-hospital mortality, and discharge destination as RSC patients with follow-up. OSH patients without follow-up had similar rates of prestroke ambulation, use of telestroke, symptomatic ICH, in-hospital mortality, and discharge destination as OSH patients with follow-up. There was a trend toward OSH patients without follow-up to be older, have lower NIHSS, and more systemic hemorrhage after IV tPA.
Overall, 34.8% of IV tPA patients achieved a mRS of 0 to 1, and 32.5% were dead. In multivariate analysis, there was no difference in the likelihood of achieving a lower mRS score at follow-up between those who started IV tPA at the RSC versus the OSH (Table 3) , when stratified by the time to follow-up, adjusted for differences in age, time to tPA treatment, and NIHSS, with or without in-hospital deaths. Only age (0.97 per 1 year) and initial NIHSS (0.93 per 1 point) were independently associated with achieving a lower mRS.
Among the 181 OSH cases, 31.0% achieved a mRS of 0 to 1, and 34% died. Supervision of tPA was by telestroke in 84 (46.4%) and telephone in 97 (53.6%) patients. In the telestroke group, there were significantly more octogenarians (45.2% versus 26.8%, Pϭ0.01) and a trend toward more smoking. The unadjusted sICH rate (4.76% versus 3.09%, Pϭ0.56), overall mortality (10.71 versus 18.56, Pϭ0.14) and discharge outcomes among survivors were not different between telestroke versus telephone, however mortality among the octogenarians was significantly lower in the telestroke group (18.4% versus 42.3%, Pϭ0.05; Table 4 ). In the multivariate analysis, there was no difference in the likelihood of achieving a lower follow-up mRS score for telestroke versus telephone, adjusted for differences in age, time to tPA treatment and NIHSS, with or without in-hospital deaths (Table 5 ). Only age (0.98 per one year) was independently associated with achieving a lower mRS.
Discussion
This study suggests that the current "drip and ship" practice of starting IV tPA at outlying hospitals followed by rapid transfer to a stroke center is safe and feasible compared to initiation of tPA at a regional stroke center. In our study, treatment complications such as sICH, mortality, discharge outcomes, and long-term functional outcomes were no different between OSH and RSC patients. The mortality rates observed in our small retrospective series of patients were greater than seen in randomized clinical trials of intravenous tPA use. This may be attributable to patients with more severe deficits at baseline (median NIHSS of 12) and no upper age limit for tPA use, both important predictors of outcome in acute ischemic stroke. Over 30% of the patients in this series were greater than 80 years of age. Because the available data suggest a dismal outcome in older patients with severe stroke who are untreated, it is our policy to offer all patients the option of IV tPA if they qualify for treatment regardless of age and NIHSS. We could not control for the factors that may have led families to request a withdrawal of life-sustaining treatments due to poor neurological prognosis. There were important baseline imbalances with older and more severe strokes treated at the RSC, but after adjustment, complication rates and mortality did not differ between OSH and RSC. Taken together, these findings are consistent with prior reports that suggest that "drip and ship" 
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approaches can be effectively implemented in a variety of environments. 9, 11, 12, 18, 10 There were more octogenarians treated via telestroke than telephone, perhaps reflecting the increased willingness by emergency physicians to offer IV tPA to older patients based on telestroke support. Telestroke has recently been shown to be superior to telephone in accurate decision-making for IV tPA 19, 20 and may provide greater reassurance to referring physicians who treat relatively few patients. It is also readily accepted by patients, who express confidence in the remote management of their conditions via telestroke. 21 Despite the significantly higher number of octogenarians in the telestroke versus telephone group, their mortality was significantly lower and this difference was not attributable to eligibility protocol violations. Taking into account the older age and higher stroke severity in the telestroke group, our outcomes are in line with those of previously published series of conventionally treated 22 and telemedically-treated 23 patients.
It has been shown that participation in a national stroke quality improvement program increases adherence to evidencebased guidelines, 14 and it is likely that increased adherence to these measures will reduce in-hospital complications and perhaps improve long term functional outcomes for patients with acute ischemic stroke. These include recommended interventions such as deep vein thrombosis prevention, early antithrombotic therapy, lipid management, dysphagia screening, smoking cessation counseling, anticoagulation for atrial fibrillation, early rehabilitation assessment and services, and patient education. 24 Therefore, many stroke patients may benefit from transfer from a spoke hospital to an RSC that is engaged in a structured national stroke quality improvement program. Initial studies validated the reliability of the telemedicineenabled ("telestroke") assessment of the NIHSS 15, [25] [26] [27] in both subacute and acute ischemic stroke patients. A single prior study suggested that IV tPA supervised via telephone may be feasible and time-efficient, although there are limited data on long-term outcomes comparing these patients to those who arrive directly to the RSC. 8 Recently, there has been increased attention on telestroke as a means to facilitate increased access to acute stroke care for rural or neurologically underserved areas. 28, 29 The Center for Medicare and Medicaid Services recently issued a new administrative V code (V45.88 "Status post administration of tPA in a different facility within the last 24 hours before admission to current facility") to permit tracking of this "drip and ship" practice, and potentially address the reimbursement inequity created in this scenario in which neither the spoke nor hub hospital receives the appropriate higher diagnosis-related group payment (DRG 61 to 63). Our study provides additional scientific support for this "drip and ship" approach.
Because the benefit of tPA diminishes rapidly with increased time to treatment, 30 -32 "drip and ship" should improve treatment rates and outcomes compared to transfer to RSCs for tPA. 6 Many smaller hospitals have used telestroke "drip and ship" approaches to overcome physician reluctance 5,13,33,34 and become "tPA-capable" centers. 35 The results from our study suggest complication rates are comparable to that of the NINDS IV tPA trial 1 despite a substantially older population.
Our study has some potential limitations. It is a retrospective series and therefore may not be adequately powered to detect significant differences in complications or outcomes between the groups at spoke versus hub hospitals or between telephone and telestroke consultation. To control for any difference associated with hospital inpatient care processes, we only included those patients treated with IV tPA at an outside hospital if they were subsequently transferred to our RSC hub. In this manner, all patients had the same post-tPA care and secondary prevention opportunities. Therefore, these results may not apply to patients who receive IV tPA under remote supervision but remain at an OSH ("drip and keep") that is not a fully equipped stroke center. The data from the TeMPIS project in Bavaria 23 strongly supports the "drip and keep" model if the use of telemedicine can fill in the missing pieces to make a functioning OSH stroke unit, but we have no data on the outcomes of patients who remain at an OSH that functions below the level of a stroke unit or primary stroke center. We do not have data on the number of patients who presented to referring hospitals with acute stroke suspect who were not discussed using telemedicine. Nevertheless, based on our rates of treatment with intravenous thrombolysis (13% of all telemedicine and telephone consults and 24% of acute ischemic stroke diagnoses from outside referring hospitals within the time period of this study) which is at or above the range of the reported rates of t-PA use in community hospitals, 36 we believe that outside hospital emergency physicians are contacting our system for most of the acute stroke suspects evaluated in their emergency room. Previous studies from our group also suggest that referring emergency physicians involved in our program endorse the quality of our Telestroke system and felt confident managing patients with telemedicine support, therefore we do think that our hospital is contacted for the majority of the acute stroke suspects that present to our referring hospitals emergency departments. 9 Also, because our study design deliberately excluded those patients who underwent rescue reperfusion therapy for failed IV tPA, additional studies would need to be performed to address that population. Lastly, our follow-up mRS data were limited because of the different times that follow-up was available, and the lack of follow-up data in 20% of the patients. Six-and 12-month outcomes incorporates some variability due to comorbidities and rehabilitation interventions. We do not have data on rehabilitation duration and quality provided to our patients. Reassuringly, the group without follow-up was similar in most ways to those patients with follow-up assessment, there were no differences in the follow-up data distribution nor in inpatient rehabilitation use between the OSH and RSC hub patients, and we used a statistical approach to try to maximize the follow-up information available.
In summary, these results suggest that the "drip and ship" model of IV tPA treatment is safe and can be readily applied to a wide variety of hospital settings for acute stroke patients who arrive within 3 hours of stroke symptom onset. With only 4 neurologists per 100 000 persons in the United States, and recent evidence suggesting IV tPA is effective up to 4.5 hours after symptom onset, 37, 38 remote support of intravenous thrombolysis will play a crucial role in meeting an ever-growing demand.
Disclosures
The Massachusetts General Hospital (MGH) operates a multispecialty telemedicine clinical care program, and spoke hospitals contract with the MGH for access to these professional services. В экспериментальных исследованиях было пока-зано, что ионы железа участвуют в развитии повреж-дения головного мозга после внутримозгового кро-воизлияния (ВМК). Свободные ионы железа высво-бождаются в результате лизиса эритроцитов и из депо ферритина и могут играть определенную роль в раз-витии оксидантного стресса, высвобождении глута-мата и воспалительной реакции после геморрагичес-кого повреждения головного мозга [1] [2] [3] . Хелаторы железа, такие как дефероксамин, могут уменьшить отек мозга и улучшить функциональный исход в экс-периментальных моделях ВМК [4] .
Существует немного данных относительно кли-нических доказательств токсичности ионов железа у пациентов с ВМК [5] . Мы собрали полученные нами данные с целью проверки корреляции уровня ферри-тина сыворотки крови с неблагоприятным исходом у пациентов с ВМК.
■ ПАЦИЕНТЫ И МЕТОДЫ
Проспективно изучили данные 100 произвольно отобранных пациентов с первичным супратенто-риальным ВМК, поступивших в первые 12 часов от момента появления симптомов в одну их трех клиник в течение одного года. Критериями исключе-ния были: наличие инвалидности, злоупотребление алкоголем, наличие воспалительных или инфекци-онных заболеваний печени, почек, гематологических или онкологических заболеваний, повторное внутри-мозговое кровоизлияние и поступление в состоянии комы. Также из исследования исключили 3 паци-ентов, утерянных для последующих наблюдений, и 5 пациентов, у которых по результатам компьютер-ной томографии (КТ) головного мозга при поступ-лении не удалось классифицировать кровоизлияние по объему. Исследование было одобрено комитетами по этике участвующих центров. Информированное согласие подписали все участники исследования или их родственники. Все пациенты поступали в отде-ления острого инсульта и получали лечение в соот-ветствии с рекомендациями European Stroke Initiative [6] . Тяжесть инсульта количественно оценивали по шкале инсульта Национальных институтов здра-воохранения (NIHSS). Функциональные исходы оце-нивали через 3 месяца по модифицированной шкале Рэнкина (МШР), и неблагоприятным считали исход при оценке по МШР >2 баллов.
Компьютерную томографию головы выполняли при поступлении, через 72 часа и через 7 дней. Объем ВМК и периферической гиподенсивной зоны опре-деляли по формуле объема эллипсоида, объем зоны отека рассчитывали путем вычитания объема ВМК из общего объема зоны патологических изменений. Масс-эффект имел место в случае обнаружения асимметрии желудочков или смещения срединных структур мозга. Все результаты КТ централизованно оценивал исследователь, не располагающий клини-ческими данными. Коэффициент роста ВМК и отека рассчитывали по формуле: "окончательный объем"-"первоначальный объем"/"первоначальный объем".
Образцы сыворотки крови получали при поступле-нии, через 24 и 72 часа. Уровни ферритина в сыворот-ке крови, интерлейкина-6 (ИЛ-6) и фактора некроза опухоли α (ФНО-α) определяли методом электрохе-милюминесцентного иммуноферментного анализа (ELECSYS 2010; Roche Diagnostics и IMMULITE 1000; Diagnostic Products Corporation).
Соотношения различных показателей двух групп пациентов сравнивали с использованием критерия хи-квадрат. Распределения проверяли на нормаль-ность с помощью критерия Колмогорова-Смирнова. Непрерывные переменные выражали в виде среднего значения и стандартного отклонения (СО) или медиа-ны и квартилей и сравнивали между собой с использо-ванием критериев Стьюдента и Манна-Уитни в зави-симости от необходимости. Связь между содержанием ферритина и непрерывными переменными оценива-ли с помощью коэффициента ранговой корреляции Спирмена. Для изучения влияния уровня ферритина на полный комплекс оценок порядковой МШР мы использовали общие линейные модели с внесением поправок на факторы и переменные, связанные с дихо-томизированной шкалой Рэнкина (неблагоприятный исход, оценка по МШР >2 баллов), которые были выявлены по результатам однофакторного анализа. Мы адаптировали модели с учетом ряда особенностей посредством метода Enter. Значения при р<0,05 счита-ли статистически значимыми во всех тестах.
■ РЕЗУЛЬТАТЫ Неблагоприятные исходы через 3 месяца наблюдали у 51 (55,4%) из 92 пациентов. Семнадцать пациентов скончались в период проведения исследования. В таб-лице 1 представлены клинические, биохимические показатели и результаты лучевых методов исследова-ния в группах в зависимости от исхода. Преклонный возраст, тяжесть инсульта, большой объем гематомы, проникновение крови в желудочки, наличие масс-эффекта и исходно повышенное содержание ИЛ-6 и ферритина были ассоциированы с неблагоприят-ным клиническим исходом. Заслуживает внимания тот факт, что чем выше квартиль ферритина, тем хуже распределение оценок по МШР (см. рисунок). С помощью общей линейной модели было показано, что при переходе в последующую квартиль концент-рации ферритина оценка по МШР увеличивалась в среднем на 1,42 балла (95% доверительный интервал [ДИ] от 1,04 до 1,69) после внесения поправок на про-гностические переменные (см. таблица 2). Эта взаимо-связь сохранялась после исключения данных 26 паци-ентов, включенных в клиническое испытание.
У пациентов с неблагоприятными исходами также обнаружили повышенный уровень ферритина в образ-це крови, взятом в течение 3 часов от момента появ-ления симптомов ВМК (р<0,001). Динамика концент-рации ферритина в первые 72 часа имела линейный характер (в среднем: 270 нг/мл -исходно, 258 нг/мл -через 24 часа и 241 нг/мл -через 72 часа). Исходные значения не коррелировали с уровнями реактантов острой фазы, такими как число лейкоцитов и концент-рации глюкозы и фибриногена в сыворотке крови.
Показана четкая корреляция исходной концент-рации ферритина с тяжестью инсульта, объемами ВМК и зоны отека на исходном уровне, через 24 часа и через 7 дней (для всех точек наблюдения r>0,60) и умеренная корреляция с уровнем ИЛ-6 (r=0,32). Концентрация ферритина коррелировала с увели-чением объема ВМК через 7 дней (r=0,27, р=0,04), но достоверной корреляции с увеличением объема зоны отека через 72 часа (r=0,24, р=0,07) или через 7 дней не выявили.
■ ОБСУЖДЕНИЕ В исследовании показали, что повышение уровня ферритина в сыворотке крови, в первые 12 часов от момента появления симптмов ВМК является пре-диктором развития неблагоприятного исхода у паци-ентов с ВМК. Кроме того, высокий уровень ферри-тина был ассоциирован с развитием неблагоприят-ных исходов у пациентов с острым ишемическим инсультом [7] , а также с повышенным риском разви-тия геморрагический трансформации и отека мозга у пациентов, которым проводили реперфузионную терапию [8] .
Представленные результаты наводят на мысль о негативном биологическом влиянии повышенно- данными -в моделях ВМК на животных показали, что свободные ионы железа принимают участие в образова-нии гидроксильных радикалов, развитии воспалитель-ной реакции и раннего отека головного мозга [1] [2] [3] . Уровень ферритина в сыворотке крови может час-тично повышаться на фоне ответа острой фазы [9] . Тем не менее различия в уровнях ферритина у паци-ентов с благоприятными и неблагоприятными исхо-дами наблюдали в течение первых 3 часов от момен-та появления симптомов инсульта. Концентрация ферритина оставалась стабильной в последующий период. Кроме того, в соответствии с результатами ранее проведенных исследований, при ишемическом инсульте [10] не обнаружили никакой корреляци-онной связи между содержанием ферритина и реак-тантов острой фазы, а влияние на исход сохранялось после внесения поправок на специфические показа-тели острого воспаления.
Главный интерес проведенного исследования связан с потенциальной терапевтической возможностью свя-зывания ионов железа в хелатные комплексы. В экспе-риментальных исследованиях был показан нейропро-текторный эффект дефероксамина при геморрагичес-ком повреждении головного мозга, заключающийся в уменьшении отека головного мозга и неврологичес-ких нарушений [4] . Эти доклинические данные о бла-готворном влиянии железомодифицирующих добавок подтверждают нейротоксическую роль ионов железа в повышенной концентрации. Тем не менее проведен-ное нами исследование имеет некоторые ограниче-ния. Анализ данных нейровизуализации недостаточен и требует более широкого изучения, мы не использова-ли планиметрическое измерение объема зоны пораже-ния, являющееся более точным методом, чем оценка по формуле объема эллипсоида.
■ ЗАКЛЮЧЕНИЕ
Таким образом, настоящее исследование демон-стрирует, что уровень ферритина в сыворотке крови является важным предиктором клинических исходов у пациентов с первичным ВМК. Эти данные свиде-тельствуют о нейротоксической роли ионов железа и позволяют разработать новые терапевтические стра-тегии для лечения ВМК. Поскольку наше исследова-ние было обсервационным, причинную взаимосвязь необходимо доказать в интервенционных клинических испытаниях по изменению содержания ионов железа.
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